GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease

Nature Medicine

Volumn 20, Issue 8, 2014, Pages 886-896

  Jo, Seonmi ^a,b   Yarishkin, Oleg ^b   Hwang, Yu Jin ^b   Chun, Ye Eun ^b,c   Park, Mijeong ^b,c   Woo, Dong Ho ^b   Bae, Jin Young ^d   Kim, Taekeun ^b   Lee, Jaekwang ^b   Chun, Heejung ^b   Park, Hyun Jung ^e   Lee, Da Yong ^b   Hong, Jinpyo ^b   Kim, Hye Yun ^b   Oh, Soo Jin ^b   Park, Seung Ju ^b   Lee, Hyo ^b   Yoon, Bo Eun ^b   Kim, Youngsoo ^b   Jeong, Yong ^a   Shim, Insop ^e   Bae, Yong Chul ^d   Cho, Jeiwon ^b,c   Kowall, Neil W ^f,g   Ryu, Hoon ^b,f,g   Hwang, Eunmi ^b   Kim, Daesoo ^a   Lee, C Justin ^b,c,h   more..

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

^d Kyungpook National University   (South Korea)

^e Kyung Hee University   (South Korea)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VA BOSTON HEALTHCARE SYSTEM   (United States)

^h Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASTROCYTES; CEREBELLUM; DENTATE GYRUS; DISEASE MODELS, ANIMAL; EYE PROTEINS; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; HUMANS; ION CHANNELS; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, TRANSGENIC; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PUTRESCINE; RECEPTORS, GABA; RNA, SMALL INTERFERING;

EID: 84905822105     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3639     Document Type: Review

References (70)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168 (2012).
2. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004). (Pubitemid 39061671)
3. Mucke, L. & Selkoe, D.J. Neurotoxicity of amyloid b-protein: Synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338 (2012).
4. Ballatore, C., Lee, V.M.-Y. & Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672 (2007). (Pubitemid 47283144)
5. Eddleston, M. & Mucke, L. Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience 54, 15-36 (1993). (Pubitemid 23147085)
6. Wisniewski, H.M. & Wegiel, J. Spatial relationships between astrocytes and classical plaque components. Neurobiol. Aging 12, 593-600 (1991).
7. Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638-647 (2009).
8. Kuchibhotla, K.V., Lattarulo, C.R., Hyman, B.T. & Bacskai, B.J. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211-1215 (2009).
9. Woo, D.H. et al. TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation. Cell 151, 25-40 (2012).
10. Henneberger, C., Papouin, T., Oliet, S.H. & Rusakov, D.A. Long-term potentiation depends on release of d-serine from astrocytes. Nature 463, 232-236 (2010).
11. Blum, A.E., Joseph, S.M., Przybylski, R.J. & Dubyak, G.R. Rho-family GTPases modulate Ca2+-dependent ATP release from astrocytes. Am. J. Physiol. Cell Physiol. 295, C231-C241 (2008). (Pubitemid 352755803)
12. Lee, S. et al. Channel-mediated tonic GABA release from glia. Science 330, 790-796 (2010).
13. Farrant, M. & Nusser, Z. Variations on an inhibitory theme: Phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci. 6, 215-229 (2005). (Pubitemid 40342416)
14. Samakashvili, S. et al. Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease. Electrophoresis 32, 2757-2764 (2011).
15. Yoshiike, Y. et al. GABAA Receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS ONE 3, e3029 (2008).
16. Yoon, B.E. et al. The amount of astrocytic GABA positively correlates with the degree of tonic inhibition in hippocampal CA1 and cerebellum. Mol. Brain 4, 42 (2011).
17. Borchelt, D.R. et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945 (1997). (Pubitemid 27471397)
18. Kamphuis, W. et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE 7, e42823 (2012).
19. Volianskis, A., Køstner, R., Mølgaard, M., Hass, S. & Jensen, M.S. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1DE9-deleted transgenic mice model of b-amyloidosis. Neurobiol. Aging 31, 1173-1187 (2010).
20. Irizarry, M.C. et al. Ab deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 7053-7059 (1997). (Pubitemid 27427884)
21. Matousek, S.B. et al. Chronic IL-1b-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J. Neuroimmune Pharmacol. 7, 156-164 (2012).
22. Hartlage-Rübsamen, M. et al. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Ab deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol. 121, 705-719 (2011).
23. Kesner, R.P. A behavioral analysis of dentate gyrus function. Prog. Brain Res. 163, 567-576 (2007). (Pubitemid 47321453)
24. Nakashiba, T. et al. Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell 149, 188-201 (2012).
25. Cao, D., Lu, H., Lewis, T.L. & Li, L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 282, 36275-36282 (2007).
26. Han, K.-S. et al. Channel-mediated astrocytic glutamate release via Bestrophin-1 targets synaptic NMDARs. Mol. Brain 6, 4 (2013).
27. Park, H. et al. High glutamate permeability and distal localization of Best1 channel in CA1 hippocampal astrocyte. Mol. Brain 6, 54 (2013).
28. Seiler, N., Sshmidt-Glenewinkel, T. & Sarhan, S. On the formation of g-aminobutyric acid from putrescine in brain. J. Biochem. 86, 277-279 (1979).
29. Laschet, J., Grisar, T., Bureau, M. & Guillaume, D. Characteristics of putrescine uptake and subsequent GABA formation in primary cultured astrocytes from normal C57BL/6J and epileptic DBA/2J mouse brain cortices. Neuroscience 48, 151-157 (1992).
30. Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 40, D742-D753 (2012).
31. Seiler, N. & Al-Therib, M. Putrescine catabolism in mammalian brain. Biochem. J. 144, 29-35 (1974).
32. Saura, J. et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62, 15-30 (1994). (Pubitemid 24287342)
33. Nakamura, S. et al. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol. 80, 419-425 (1990). (Pubitemid 20255767)
34. Saura, J., Kettler, R., Da Prada, M. & Richards, J. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 12, 1977-1999 (1992).
35. Levitt, P., Pintar, J.E. & Breakefield, X.O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. USA 79, 6385-6389 (1982). (Pubitemid 13214252)
36. Birkmayer, W., Riederer, P., Youdim, M. & Linauer, W. The potentiation of the anti akinetic effect after l-dopa treatment by an inhibitor of MAO-B, Deprenil. J. Neural Transm. 36, 303-326 (1975).
37. Youdim, M.B. et al. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79, 172-179 (2005). (Pubitemid 40116432)
38. Nägga, K., Bogdanovic, N. & Marcusson, J. GABA transporters (GAT-1) in Alzheimer's disease. J. Neural Transm. 106, 1141-1149 (1999). (Pubitemid 30009212)
39. Lee, J., Kannagi, M., Ferrante, R.J., Kowall, N.W. & Ryu, H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. FASEB J. 23, 1739-1749 (2009).
40. Turrigiano, G.G. The self-tuning neuron: Synaptic scaling of excitatory synapses. Cell 135, 422-435 (2008).
41. Allen, C. & Stevens, C.F. An evaluation of causes for unreliability of synaptic transmission. Proc. Natl. Acad. Sci. USA 91, 10380-10383 (1994). (Pubitemid 24329000)
42. Gimbel, D.A. et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30, 6367-6374 (2010).
43. De Angelis, L. & Furlan, C. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test. Pharmacol. Biochem. Behav. 65, 649-653 (2000). (Pubitemid 30182507)
44. Wilcock, G.K., Birks, J., Whitehead, A. & Evans, S.J. The effect of selegiline in the treatment of people with Alzheimer's disease: A meta?analysis of published trials. Int. J. Geriatr. Psychiatry 17, 175-183 (2002). (Pubitemid 34130310)
45. Engberg, G., Elebring, T. & Nissbrandt, H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J. Pharmacol. Exp. Ther. 259, 841-847 (1991).
46. Marzo, A. et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res. 50, 77-85 (2004). (Pubitemid 38479671)
47. Squire, L.R., Stark, C.E. & Clark, R.E. The medial temporal lobe*. Annu. Rev. Neurosci. 27, 279-306 (2004). (Pubitemid 39050405)
48. Palop, J.J., Chin, J. & Mucke, L. A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768-773 (2006). (Pubitemid 44622680)
49. Pike, C.J., Cummings, B., Monzavi, R. & Cotman, C.W. b-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience 63, 517-531 (1994).
50. Chen, G. et al. A learning deficit related to age and b-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408, 975-979 (2000). (Pubitemid 32101643)
51. Hsieh, H. et al. AMPAR removal underlies Ab-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843 (2006). (Pubitemid 44828454)
52. Scheff, S.W. & Price, D.A. Synaptic density in the inner molecular layer of the hippocampal dentate gyrus in Alzheimer disease. J. Neuropathol. Exp. Neurol. 57, 1146-1153 (1998). (Pubitemid 28562743)
53. Jacobs, K., Kharazia, V.N. & Prince, D.A. Mechanisms underlying epileptogenesis in cortical malformations. Epilepsy Res. 36, 165-188 (1999). (Pubitemid 29457579)
54. Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708-721 (2012).
55. Piccinin, G.L., Finali, G. & Piccirilli, M. Neuropsychological effects of l-deprenyl in Alzheimer's type dementia. Clin. Neuropharmacol. 13, 147-163 (1990). (Pubitemid 20109359)
56. Tariot, P.N. et al. l-deprenyl in Alzheimer's disease: Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry 44, 427-433 (1987). (Pubitemid 17064487)
57. Monteverde, A., Gnemmi, P., Rossi, F. & Finali, G. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin. Ther. 12, 315-322 (1990). (Pubitemid 20287913)
58. Birks, J. & Flicker, L. Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev. CD000442 (2003).
59. Gerlach, M., Youdim, M. & Riederer, P. Pharmacology of selegiline. Neurology 47, S137-S145 (1996). (Pubitemid 26422579)
60. Barres, B.A. The mystery and magic of glia: A perspective on their roles in health and disease. Neuron 60, 430-440 (2008).
61. Paxinos, G. & Franklin, K. The Mouse Brain in Stereotaxic Coordinates: Compact Second Edition. (Academic Press, San Diego, 2003).
62. Kutlán, D. & Molnar-Perl, I. New aspects of the simultaneous analysis of amino acids and amines as their o-phthaldialdehyde derivatives by high-performance liquid chromatography. Analysis of wine, beer and vinegar. J. Chromatogr. A 987, 311-322 (2003). (Pubitemid 36140107)
63. Mengerink, Y., Kutlan, D., Toth, F., Csampai, A. & Molnar-Perl, I. Advances in the evaluation of the stability and characteristics of the amino acid and amine derivatives obtained with the o-phthaldialdehyde/3- mercaptopropionic acid and o-phthaldialdehyde/N-acetyl-l-cysteine reagents. High-performance liquid chromatography-mass spectrometry study. J. Chromatogr. A 949, 99-124 (2002). (Pubitemid 34183420)
64. Kim, Y.S., Moss, J.A. & Janda, K.D. Biological tuning of synthetic tactics in solid-phase synthesis: Application to Ab (1-42). J. Org. Chem. 69, 7776-7778 (2004). (Pubitemid 39403374)
65. Unal Cevik, I. & Dalkara, T. Intravenously administered propidium iodide labels necrotic cells in the intact mouse brain after injury. Cell Death Differ. 10, 928-929 (2003). (Pubitemid 36939703)
66. Park, H. et al. Bestrophin-1 encodes for the Ca2+-activated anion channel in hippocampal astrocytes. J. Neurosci. 29, 13063-13073 (2009).
67. Fujiwara, K., Tanabe, T., Yabuuchi, M., Ueoka, R. & Tsuru, D. A monoclonal antibody against the glutaraldehyde-conjugated polyamine, putrescine: Application to immunocytochemistry. Histochem. Cell Biol. 115, 471-477 (2001). (Pubitemid 32662422)
68. Sehgal, N. et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. USA 109, 3510-3515 (2012).
69. Hong, J. et al. Microglial Toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death. J. Biol. Chem. 285, 39447-39457 (2010).
70. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCT method. Methods 25, 402-408 (2001). (Pubitemid 34164012)